Form 4: Sarepta Therapeutics Executive Louise Rodino-Klapac Reports Acquisition of Performance-Based Stock Units
SEC Form 4 Filing
Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports the acquisition of 3,500 performance-based stock units that will vest in March 2025.
Summary
- This is a Form 4 filing indicating a change in beneficial ownership of securities at Sarepta Therapeutics by Louise Rodino-Klapac, the Head of R&D and CSO.
- On February 11, 2025, Rodino-Klapac acquired 3,500 Performance Restricted Stock Units (PSUs).
- These PSUs were earned under an award granted on March 6, 2023, based on the Compensation Committee's assessment of Sarepta's achievement of specific milestones.
- The PSUs will vest on March 6, 2025, contingent upon Rodino-Klapac's continued service to the company.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The acquisition of PSUs by a key executive is generally a good sign, indicating confidence in the company's future performance. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's prospects.
Positives
- The acquisition of PSUs by a key executive suggests confidence in the company's performance and future prospects.
- The vesting of the PSUs is tied to continued service, aligning the executive's interests with the long-term success of the company.
Future Outlook
The vesting of the PSUs on March 6, 2025, is contingent upon the Reporting Person's continued service to the Company.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates that a key executive's compensation is tied to the company's performance.
Stakeholder Impact
- The acquisition of PSUs by a key executive aligns their interests with those of shareholders, as their compensation is tied to the company's performance.
Key Dates
| Date | Description |
|---|---|
| 2023-03-06 | Date the PSU award was granted to the Reporting Person |
| 2025-02-11 | Date of transaction: acquisition of Performance Restricted Stock Units |
| 2025-03-06 | Vesting date of the earned PSUs, subject to continued service |
| 2025-02-13 | Date of signature for the Form 4 filing |
Keywords
Sarepta Therapeutics, Form 4, Beneficial Ownership, Louise Rodino-Klapac, Performance Stock Units, PSU, SRPT, Compensation Committee, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.